This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

P. A. L. SCOTT, M.B., Ch.B.; L. GRIMSHAW, M.B., Ch.B.; H. M. P. MOLONY, M.B., Ch.B.

AMA Arch Intern Med. 1957;100(3):484-486.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Meprobamate ( 2-methyl-2-n-propyl-1,3-propanediol dicarbamate), marketed in the United Kingdom as Equanil, Miltown, and Mepavlon, is in common use as a tranquilizer in psychiatric states characterized by anxiety and tension. Berger, from whose laboratories it comes, describes three pharmacological properties: a muscle-relaxant action, an anticonvulsant action, and a tranquilizing action. He states that it acts on the central nervous system only, without affecting autonomic functions; it seems to have a unique selective action on the thalamus.

Clinical evaluation is far from complete, but meprobamate seems to be more effective in neurotic than in psychotic conditions. It seemed to us to have two advantages over chlorpromazine: It acted much more quickly when given orally, and it was reported to have no troublesome complications, such as jaundice or agranulocytosis. Berger stated that drowsiness, seldom inconvenient, and infrequent allergic reactions were the only side-effects. More recently, however, Friedman and Marmelzat have described cutaneous, muscular, gastrointestinal, . . . [Full Text PDF of this Article]

Author Affiliations
Manchester, England

Department of Psychiatry, Manchester Royal Infirmary.

Footnotes
Accepted for publication April 11, 1957.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?